LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

LLY

1,014.8

-0.06%↓

JNJ

230.4

+0.37%↑

ABBV

213.61

-0.27%↓

UNH

383.39

-1.88%↓

AZN

187.85

+1.77%↑

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

48.05 0.31

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

47.16

Max

48.82

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 49.701
EPS	0.208
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+30.71% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4.9M 2.8B
Iepriekšējā atvēršanas cena	47.74
Iepriekšējā slēgšanas cena	48.05

Ziņu noskaņojums

By Acuity

58%

42%

293 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. maijs 20:36 UTC

Iegādes, apvienošanās, pārņemšana

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

2026. g. 19. maijs 23:47 UTC

Tirgus saruna

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

2026. g. 19. maijs 23:34 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 19. maijs 23:28 UTC

Tirgus saruna

Peļņas

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 19. maijs 23:28 UTC

Tirgus saruna

Peļņas

F&P Healthcare's Outlook Key for Investors -- Market Talk

2026. g. 19. maijs 23:10 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 19. maijs 23:10 UTC

Tirgus saruna

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

2026. g. 19. maijs 22:02 UTC

Peļņas

ZTO Express (Cayman): Di Xu to Resign From Board

2026. g. 19. maijs 22:01 UTC

Peļņas

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

2026. g. 19. maijs 22:01 UTC

Peļņas

ZTO Express (Cayman) 1Q EPS 39c >ZTO

2026. g. 19. maijs 22:00 UTC

Peļņas

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

2026. g. 19. maijs 21:37 UTC

Peļņas

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

2026. g. 19. maijs 21:31 UTC

Iegādes, apvienošanās, pārņemšana

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

2026. g. 19. maijs 21:01 UTC

Peļņas

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

2026. g. 19. maijs 20:58 UTC

Peļņas

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

2026. g. 19. maijs 20:46 UTC

Karstas akcijas

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

2026. g. 19. maijs 20:43 UTC

Tirgus saruna

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

2026. g. 19. maijs 20:34 UTC

Peļņas

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

2026. g. 19. maijs 20:32 UTC

Peļņas

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

2026. g. 19. maijs 20:32 UTC

Peļņas

James Hardie Industries 4Q EPS 5c >JHX

2026. g. 19. maijs 20:32 UTC

Peļņas

James Hardie Industries 4Q Sales $1.4B >JHX

2026. g. 19. maijs 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Analog Devices to Buy Empower Semiconductor for $1.5B

2026. g. 19. maijs 20:18 UTC

Tirgus saruna

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

2026. g. 19. maijs 20:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 19. maijs 20:13 UTC

Tirgus saruna

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

2026. g. 19. maijs 20:03 UTC

Iegādes, apvienošanās, pārņemšana

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

2026. g. 19. maijs 20:03 UTC

Iegādes, apvienošanās, pārņemšana

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

2026. g. 19. maijs 20:02 UTC

Iegādes, apvienošanās, pārņemšana

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

2026. g. 19. maijs 20:02 UTC

Iegādes, apvienošanās, pārņemšana

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

2026. g. 19. maijs 19:23 UTC

Tirgus saruna

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

30.71% augšup

Prognoze 12 mēnešiem

Vidējais 63.17 USD 30.71%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

293 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.